A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension
Latest Information Update: 25 May 2026
At a glance
- Drugs QLS 1410 (Primary)
- Indications Resistant hypertension
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 22 May 2026 Status changed from not yet recruiting to recruiting.
- 31 Mar 2026 New trial record